Baloxavir safety and clinical and virologic outcomes in influenza virus-infected pediatric patients by age group: age-based pooled analysis of two pediatric studies conducted in Japan

Table 4 Summary of viral titer (log₁₀ TCID₅₀/ml) by age group and influenza virus type (subtype)

Study day		A(H1N1)pdm09		A(H3N2)		B
Study day		< 6 years N = 9	≥6 to < 12 years N = 4	< 6 years N = 27	≥6 to < 12 years N = 69	< 6 years N = 16	≥6 to < 12 years N = 4
Day 1	n	8	4	27	69	16	4
Day 1	Mean (SD)	6.34 (1.70)	5.65 (2.12)	5.29 (1.56)	5.22 (1.99)	6.02 (1.35)	4.35 (2.55)
Day 2	n	8	4	27	69	16	4
Day 2	Mean (SD)	0.96 (0.54)	1.40 (1.40)	1.04 (0.82)	0.83 (0.44)	2.14 (1.47)	1.65 (1.32)
Day 3	n	6	1	18	39	7	3
Day 3	Mean (SD)	0.70 (0)	1.3 (−)^a	0.75 (0.15)	0.75 (0.24)	2.69 (1.63)	2.30 (2.77)
Day 4	n	4	3	11	41	10	2
Day 4	Mean (SD)	1.10 (0.62)	0.80 (0.17)	1.28 (1.34)	0.78 (0.29)	3.98 (1.96)	0.70 (0)
Day 6	n	8	4	27	69	16	4
Day 6	Mean (SD)	0.83 (0.35)	1.60 (1.43)	2.07 (1.37)	0.86 (0.62)	2.19 (1.52)	0.70 (0)
Day 9	n	8	4	27	69	16	4
Day 9	Mean (SD)	0.83 (0.35)	0.70 (0)	1.25 (1.10)	0.70 (0)	0.70 (0)	0.70 (0)

Detection limit of virus titer: 0.7 log₁₀ TCID₅₀/ml
The subset of patients who were positive for influenza virus titer at baseline was included in this analysis
SD standard deviation; TCID₅₀: 50% tissue culture infective dose
^aSD not calculable because n = 1

ISSN: 1471-2431